WILMINGTON, N.C., June 24 /PRNewswire-FirstCall/ --
aaiPharma Inc. (Nasdaq: AAII) announced today that the Company is
launching Darvon(R) Compound 32 (propoxyphene hydrochloride, aspirin and
caffeine).
Darvon(R) Compound 32 offers a lower dose (i.e., 32 mg of propoxyphene)
alternative to Darvon(R) Compound 65 (i.e., 65 mg of propoxyphene), providing
physicians with more options and increased titration flexibility to aid in the
management of headache pain. This product expands aaiPharma's current
portfolio of semi-exclusive Darvon(R) branded products, and further focuses
the Company's sales and marketing efforts. Since the acquisition and launch
of the Darvon(R)/Darvocet-N(R) brand family, aaiPharma has grown the semi-
exclusive portion of the franchise significantly, with a 125 percent increase
in TRx Extended Units for the semi-exclusive Darvon(R) products year-to-date
(January 2003 through May 2003) over the same time period in 2002.
"We are very pleased to announce our launch of the first of the
Darvon(R)/Darvocet-N(R) line extensions we committed to developing when we
acquired these products last year," commented Dr. Philip Tabbiner, President
and CEO of aaiPharma. "Darvon(R) Compound 32 marks the first of these branded
products to be manufactured exclusively by aaiPharma and also reflects the
hard work of our method development and validation teams within AAI
Development Services."
About aaiPharma
aaiPharma Inc. is a leading, science-based specialty pharmaceutical
company with corporate headquarters in Wilmington, North Carolina. With more
than 23 years of drug development expertise and a proven sales and marketing
track record, the Company is focused on acquiring, improving and marketing
well-known, branded medicines in pain management, gastroenterology and
critical care. In addition to its branded product portfolio and robust
pipeline, aaiPharma continues to offer comprehensive drug development services
to the pharmaceutical, biotechnology, generic and device industries through
its services division, AAI Development Services. For more information, please
visit aaiPharma's website at http://www.aaipharma.com.
Forward Looking Statements
Information in this press release contains certain "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities and Exchange Act of 1934, including
statements concerning the future medical and commercial significance and
attractiveness of the newly launched product, and the future development,
regulatory approval, commercialization and growth of products in the Company's
pipeline and its product portfolio (including Darvon(R) Compound and other
Darvon(R) and Darvocet-N(R) products and line extensions). The "forward-
looking statements" herein involve risks and uncertainties that could cause
actual results to differ materially, including, without limitation, risks and
uncertainties pertaining aaiPharma's ability to successfully develop, improve,
obtain timely regulatory approval for, and profitably sell pharmaceutical
products (including Darvon(R) Compound). Additional factors that may cause
the actual results to differ materially are discussed in aaiPharma's recent
filings with the Securities and Exchange Commission, including, but not
limited to, its Annual Report on Form 10-K filed on March 28, 2003, including
its Exhibit 99.1 and other exhibits; its Form 10-Q filed on May 15, 2003, its
Form 8-Ks; and its other periodic filings.
Darvon(R) and Darvocet-N(R) are registered trademarks owned by aaiPharma
Inc.
SOURCE aaiPharma Inc.
 back to top
Related links:
http://www.aaipharma.com
CONTACT:
Andrea L. Johnston, Vice President, Corporate
Communications, +1-910-254-7340, or James B. Sloan, Jr., Senior
Vice President, Corporate Finance, +1-910-254-7690, both of
aaiPharma Inc.
|
